Wearables and Smartphone Tools Are Reshaping How Rheumatoid Arthritis Is Monitored
A narrative review shows ePROMs, wearables, and teleconsultation can track RA between visits, but engagement, validation, and workflow hurdles remain.
Riepilogo
Rheumatoid arthritis (RA) is usually monitored in clinic every few months, which can miss flares. This narrative review examines digital alternatives: electronic patient-reported outcomes (ePROMs), teleconsultation scores, consumer wearables such as Fitbit, and data-driven models. Combined PRO models distinguished active from controlled disease with AUCs up to 0.89 (0.82 in external validation). Wearable heart-rate patterns may shift before flares, and Fitbit wear compliance exceeded 90% in 150 patients. Blended care with human support worked better than app-only approaches, and digital CBT improved mental health. However, patient engagement drops over time, clinicians report workflow and interpretation concerns, and no validated action thresholds exist. The authors conclude these tools work best in combination, supported by EULAR safety principles.
Riepilogo Dettagliato
Rheumatoid arthritis is a chronic autoimmune disease with an unpredictable course, yet most monitoring still relies on outpatient visits spaced months apart. That gap limits early flare detection and makes it hard to follow treat-to-target principles. This narrative review by Karampela and Nikiphorou surveys recent evidence on digital monitoring: ePROMs, smartphone apps, teleconsultation tools, wearable sensors, and data-driven analytics.
For ePROMs, patient and clinician satisfaction was high, with fewer than 9% of patients neutral or dissatisfied, and ePROMs were linked to time savings in clinic. Combining several PROMs (patient global VAS, HAQ-DI, EQ-5D, pain) gave moderate accuracy for separating active from well-controlled disease (AUC 0.76). A refined model adding age, sex, disease duration, and selected HAQ-DI items reached an AUC of 0.89 in development and 0.82 in external validation. In teleconsultation, the RAID score correlated strongly with DAS28-CRP, with a score under 2 suggesting good control. A multimodal self-monitoring program for people at risk of RA (REMOTRA) had a 100% negative predictive value at scores under 10.
Wearables showed practical promise. Heart-rate patterns from wearables could distinguish symptomatic and inflammatory flare periods, possibly before clinical onset. Accelerometer feasibility work reported near-perfect adherence, and a Fitbit study in 150 patients over 12 weeks found wear compliance above 90% of days and activity changes tied to disease activity. Machine learning that added sensor features to PROs improved severity classification versus PROs alone. Digital CBT improved mental health scores but not pain or physical function. An app plus Fitbit plus physiotherapist counselling improved patient activation, whereas an app alone did not improve self-efficacy, which suggests blended care outperforms apps alone.
The implications are that these tools work best together rather than in isolation, and may support risk stratification, triage, and digital flare triggers. EULAR points to consider stress data protection, safety, inclusiveness, and clinician communication, and recommend that diagnosis and initiation of DMARDs occur face-to-face.
Caveats are substantial. Engagement declines over time, with half of app users dropping out by about 14.8 months in one study. Clinicians raise concerns about software awareness, data interpretation, validation, and workload. Evidence on noninferiority of remote management for disease activity and remission is conflicting. Flare definitions in wearable studies were approximate, and no standardized digital biomarkers or clinical action thresholds exist yet. As a narrative review, study selection was not systematic.
Risultati Principali
- Combined PRO model with demographics distinguished active from controlled RA: AUC 0.89 in development, 0.82 in external validation.
- Wearable heart-rate patterns distinguished flare periods and may shift before clinical disease onset, though flare definitions were approximate.
- Fitbit monitoring in 150 RA patients achieved over 90% wear compliance and captured activity changes linked to disease activity.
- App plus Fitbit plus physiotherapist counselling improved patient activation; an app alone did not improve self-efficacy.
- App engagement fell over time, with half of inflammatory arthritis users dropping out by 14.8 months.
Metodologia
This is a narrative review in Current Opinion in Rheumatology that synthesizes recent studies on ePROMs, teleconsultation, wearables, and data-driven approaches in RA. It draws on feasibility studies, randomized trials, mixed-methods work, and EULAR points to consider. No systematic search or formal quality appraisal is described.
Limitazioni dello Studio
The review is narrative and non-systematic, and cited studies are mostly small feasibility or observational designs with declining engagement and conflicting evidence on remote-care noninferiority. Wearable accuracy, standardized digital biomarkers, and actionable thresholds are not yet validated, and equity and digital literacy barriers persist.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti:
